Progressive multifocal leukoencephalopathy: A review of the neuroimaging features and differential diagnosis

European Journal of Neurology

Volumn 19, Issue 8, 2012, Pages 1060-1069

  Sahraian, M A ^a   Radue, E W ^b   Eshaghi, A ^a   Besliu, S ^c   Minagar, A ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; BETA INTERFERON; CHLORPROMAZINE; CIDOFOVIR; CYTARABINE; CYTOTOXIC AGENT; INOSITOL; INTERLEUKIN 2; MEFLOQUINE; METHYLPREDNISOLONE; MIRTAZAPINE; MONOCLONAL ANTIBODY; NATALIZUMAB; STEROID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ATAXIA; BEHCET DISEASE; BRAIN CORTEX ATROPHY; BRAIN VENTRICLE DILATATION; CEREBRAL BLINDNESS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE PARALYSIS; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; DRUG WITHDRAWAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEMIANOPIA; HEMIPARESIS; HEMIPLEGIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; MITOCHONDRIAL ENCEPHALOPATHY; MULTIPLE SCLEROSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NYSTAGMUS; OPTIC NEURITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXOPLASMOSIS; WEGENER GRANULOMATOSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; NEUROIMAGING;

EID: 84863882917     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03597.x     Document Type: Review

References (96)

1. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy: hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin's disease. Brain 1958; 81: 93-111.
2. Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science 1965; 148: 1477-1479.
3. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papovalike virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1: 1257-1260.
4. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984; 2: 299-313.
5. Holman RC, Torok TJ, Belay ED, Janssen RS, Schonberger LB. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology 1998; 17: 303-309.
6. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5: 49-73.
7. Isella V, Marzorati L, Curto N, Cappellini A, Appollonio I. Primary progressive multifocal leukoencephalopathy: report of a case. Funct Neurol 2005; 20: 139-142.
8. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71: 115-123.
9. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837-846.
10. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84: 1499-1504.
11. Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin Neurol 1999; 19: 193-200.
12. Weber T, Major EO. Progressive multifocal leukoencephalopathy molecular biology, pathogenesis and clinical impact. Intervirology 1997; 40: 98-111.
13. Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol 2011; 231: 73-77.
14. Berger JR, Houff S. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res 2006; 28: 299-305.
15. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368.
16. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
17. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381.
18. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60: 3761-3765.
19. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
20. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824.
21. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361: 1075-1080.
22. Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004; 78: 10206-10210.
23. Chowdhury M, Taylor JP, Tada H, et al. Regulation of the human neurotropic virus promoter by JCV-T antigen and HIV-1 tat protein. Oncogene 1990; 5: 1737-1742.
24. Krachmarov CP, Chepenik LG, Barr-Vagell S, Khalili K, Johnson EM. Activation of the JC virus Tat-responsive transcriptional control element by association of the Tat protein of human immunodeficiency virus 1 with cellular protein Pur alpha. Proc Natl Acad Sci U S A 1996; 93: 14112-14117.
25. Berger JR, Chauhan A, Galey D, Nath A. Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 2001; 7: 329-338.
26. Del Valle L, Croul S, Morgello S, Amini S, Rappaport J, Khalili K. Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol 2000; 6: 221-228.
27. Weber T, Weber F, Petry H, Lüke W. Immune response in progressive multifocal leukoencephalopathy: an overview. J Neurovirol 2001; 7: 311-317.
28. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186(Suppl. 2): S180-S186.
29. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005; 8: 1275.
30. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60: 162-173.
31. Shishido-Hara Y. Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease. Acta Neuropathol 2010; 120: 403-417.
32. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6: 431-441.
33. Aksamit AJ. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologists 2006; 12: 293-298.
34. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4: 59-68.
35. Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol 2007; 13: 474-476.
36. Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006; 66: 262-264.
37. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
38. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361: 1081-1087.
39. Catenoix H, Marignier R, Ritleng C, et al. Multiple sclerosis and epileptic seizures. Mult Scler 2011; 17: 96-102.
40. Weber T, Turner RW, Frye S, et al. Specific diagnosis of progressive multifocal leukoencephalopathy by polymerase chain reaction. J Infect Dis 1994; 169: 1138-1141.
41. Fong IW, Britton CB, Luinstra KE, Toma E, Mahony JB. Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol 1995; 33: 484-486.
42. McGuire D, Barhite S, Hollander H, Miles M. JC virusDNAin cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy. Ann Neurol 1995; 37: 395-399.
43. Bag AK, Curé JK, Chapman PR, Roberson GH, Shah R. JC virus infection of brain. AJNR Am J Neuroradiol 2010; 31: 1564-1576.
44. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43: 4175-4177.
45. Glass AJ, Venter M. Improved detection of JC virus in AIDS patients with progressive multifocal leukoencephalopathy by T-antigen specific fluorescence resonance energy transfer hybridization probe real-time PCR: evidence of diverse JC virus genotypes associated with progressive multifocal leukoencephalopathy in Southern Africa. J Med Virol 2009; 81: 1929-1937.
46. Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin 2008; 26: 833-854.
47. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933.
48. Whiteman ML, Post MJ, Berger JR, Tate LG, Bell MD, Limonte LP. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993; 187: 233-240.
49. Mader I, Herrlinger U. Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI. Neuroradiol 2003; 45: 717-721.
50. Arbusow V, Strupp M, Pfister HW, Seelos KC, Brückmann H, Brandt T. Contrast enhancement in progressive multifocal leukoencephalopathy: a predictive factor for long term survival. J Neurol 2000; 247: 306-308.
51. Ohta K, Obara K. Lesion extension detected by diffusion weighted magnetic resonance imaging in PML. J Neurol 2001; 248: 809-811.
52. Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 1999; 20: 1896-1906.
53. Boster A, Hreha S, Berger JR, Wanke I. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66: 593-599.
54. Kastrup O, Maschke M, Diener HC, et al. Progressive multifocal leukoencephalopathy limited to the brain stem. Neuroradiology 2002; 44: 227-229.
55. Mathew RM, Murnane M. MRI in PML: bilateral medullary lesions. Neurology 2004; 63: 2380.
56. Svensson PA, Larsson EM. Infratentorial progressive multifocal leucoencephalopathy (PML) in a patient with SLE (2008: 4b). Eur Radiol 2008; 18: 1526-1528.
57. Semmler A, Urbach H, Klockgether T, Linnebank M. Progressive multifocal leukoencephalopathy with selective involvement of the pyramidal tracts. Neurology 2007; 68: 871.
58. Sarrazin JL, Soulié D, Derosier C, Lescop J, Schill H, Cordoliani YS. MRI aspects of progressive multifocal leukoencephalopathy. J Neuroradiol 1995; 22: 172-179.
59. Mark AS, Atlas SW. Progressivemultifocal leukoencephalopathy in patients with AIDS: appearance on MR images. Radiology 1989; 173: 517-520.
60. Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 2004; 46: 22-25.
61. da Pozzo S, Manara R, Tonello S, Carollo C. Conventional and diffusionweighted MRI in progressive multifocal leukoencephalopathy: new elements for identification and follow-up. Radiol Med 2006; 111: 971-977.
62. Shah R, Bag AK, Chapman PR, Curé JK. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 2010; 65: 431-439.
63. Mukherjee P, Berman JI, Chung SW, Hess CP, Henry RG. Diffusion tensor MR imaging and fiber tractography: theoretic underpinnings. AJNR Am J Neuroradiol 2008; 29: 632-641.
64. Kuker W, Mader I, Nagele T, et al. Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control. Eur J Neurol 2006; 13: 819-826.
65. Usiskin SI, Bainbridge A, Miller RF, Jäger HR. Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy. AJNR Am J Neuroradiol 2007; 28: 285-286.
66. Huisman TA, Boltshauser E, Martin E, Nadal D. Diffusion tensor imaging in progressive multifocal leukoencephalopathy: early predictor for demyelination? AJNR Am J Neuroradiol 2005; 26: 2153-2156.
67. Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005; 2: 197-214.
68. De Stefano N, Bartolozzi ML, Guidi L, et al. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci 2005; 233: 203-208.
69. Chang L, Ernst T, Tornatore C, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997; 48: 836-845.
70. Iranzo A, Moreno A, Pujol J, et al. Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS. J Neurol Neurosurg Psychiatry 1999; 66: 520-523.
71. Yoon JH, Bang OY, Kim HS. Progressive multifocal leukoencephalopathy in AIDS: proton MR spectroscopy patterns of asynchronous lesions confirmed by serial diffusion-weighted imaging and apparent diffusion coefficient mapping. J Clin Neurol 2007; 3: 200-203.
72. Filippi M, Rocca MA. Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases. J Neuroimaging 2004; 14: 303-313.
73. Armand JP, Dousset V, Franconi JM, et al. Progressive multifocal leukoencephalopathy: study of the demyelination by magnetization transfer. J Radiol 1997; 78: 131-134.
74. Kasner SE, Galetta SL, McGowan JC, Grossman RI. Magnetization transfer imaging in progressive multifocal leukoencephalopathy. Neurology 1997; 48: 534-536.
75. Tan CS, Koralnik I. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437.
76. Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol 2001; 7: 386-390.
77. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16: 1791-1797.
78. De Luca A, Ammassari A, Pezzotti P, et al. Cidofovir in addition to antiretroviral treatment is not eff ective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22: 1759-1767.
79. Cettomai D, McArthur JC. Mirtazapine use in human immunodefi ciency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66: 255-258.
80. French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992; 6: 1293-1297.
81. McCarthy M, Nath A. Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS). Curr Neurol Neurosci Rep 2010; 10: 467-475.
82. Corral I, Quereda C, Garcia-Villanueva M, et al. Focal monophasic demyelinating leukoencephalopathy in advanced HIV infection. Eur Neurol 2004; 52: 36-41.
83. Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci 2010; 1184: 106-120.
84. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-261.
85. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72: 1458-1464.
86. Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005; 109: 449-455.
87. Vennegoor A, Wattjes MP, van Munster ETL, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011; 76: 574-576.
88. Sahraian MA, Eshaghi A. Role of MRI in diagnosis and treatment of multiple sclerosis. Clin Neurol Neurosurg 2010; 112: 609-615.
89. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799.
90. Bakshi R. Neuroimaging of HIV and AIDS related illnesses: a review. Front Biosci 2004; 9: 632-646.
91. Simone IL, Federico F, Tortorella C, et al. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry 1998; 64: 516-523.
92. Rosen L, Phillips S, Enzmann D. Magnetic resonance imaging in MELAS syndrome. Neuroradiology 1990; 32: 168-171.
93. Okun MS, Millar B, Watson R. Early diagnostic magnetic resonance imaging in acute disseminated encephalomyelitis. South Med J 2000; 93: 793-796.
94. Jennings JE, Sundgren PC, Attwood J, McCune J, Maly P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 2004; 46: 15-21.
95. Itoh K, Kano T, Nagashio C. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 1020-1022.
96. Cuvinciuc V, Martin-Blondel G, Marchou B, Bonneville F. Proton MR spectroscopy of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol 2010; 31: E69-E70.